Hansoh Pharmaceutical Group Company Limited Just Beat Revenue Estimates By 13%
Aug 22
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Healthcare Sector Analysis
UpdatedAug 24, 2025
DataAggregated Company Financials
Companies209
- 7D0.9%
- 3M45.4%
- 1Y108.3%
- YTD86.0%
Over the last 7 days, the Healthcare industry has remained flat, although notably Akeso gained 6.9%. As for the the longer term, the industry is up 108% over the past 12 months. As for the next few years, earnings are expected to grow by 32% per annum.
Sector Valuation and Performance
Has the Hong Kong Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 24 Aug 2025 | HK$2.7t | HK$1.5t | HK$38.4b | 18.7x | 71x | 1.8x |
| Tue, 22 Jul 2025 | HK$2.3t | HK$1.5t | HK$35.8b | 16.6x | 65.6x | 1.6x |
| Thu, 19 Jun 2025 | HK$2.0t | HK$1.4t | HK$33.4b | 15x | 59.6x | 1.4x |
| Sat, 17 May 2025 | HK$1.7t | HK$1.4t | HK$33.3b | 14.2x | 50.3x | 1.2x |
| Mon, 14 Apr 2025 | HK$1.5t | HK$1.4t | HK$33.6b | 13.5x | 45.6x | 1.1x |
| Wed, 12 Mar 2025 | HK$1.5t | HK$1.4t | HK$29.5b | 11.9x | 51.3x | 1.1x |
| Fri, 07 Feb 2025 | HK$1.3t | HK$1.4t | HK$29.0b | 11.2x | 46.4x | 0.9x |
| Sun, 05 Jan 2025 | HK$1.3t | HK$1.4t | HK$28.8b | 11.4x | 45.4x | 0.9x |
| Tue, 03 Dec 2024 | HK$1.4t | HK$1.4t | HK$29.2b | 12x | 46.7x | 1x |
| Thu, 31 Oct 2024 | HK$1.4t | HK$1.4t | HK$29.5b | 12.4x | 46.6x | 0.9x |
| Sat, 28 Sep 2024 | HK$1.4t | HK$1.5t | HK$30.8b | 12.5x | 45.8x | 1x |
| Mon, 26 Aug 2024 | HK$1.2t | HK$1.4t | HK$26.5b | 10.6x | 44.9x | 0.8x |
| Wed, 24 Jul 2024 | HK$1.2t | HK$1.4t | HK$27.4b | 10.9x | 44.3x | 0.9x |
| Fri, 21 Jun 2024 | HK$1.3t | HK$1.4t | HK$28.7b | 11.2x | 44.8x | 0.9x |
| Sun, 19 May 2024 | HK$1.4t | HK$1.4t | HK$28.7b | 12.1x | 49.1x | 1x |
| Tue, 16 Apr 2024 | HK$1.3t | HK$1.4t | HK$28.4b | 11x | 44.6x | 0.9x |
| Thu, 14 Mar 2024 | HK$1.4t | HK$1.4t | HK$28.3b | 11.5x | 49.1x | 1x |
| Sat, 10 Feb 2024 | HK$1.3t | HK$1.4t | HK$25.8b | 11.4x | 49.2x | 0.9x |
| Mon, 08 Jan 2024 | HK$1.5t | HK$1.4t | HK$26.4b | 12.5x | 56.5x | 1x |
| Wed, 06 Dec 2023 | HK$1.6t | HK$1.4t | HK$26.4b | 12.5x | 60x | 1.1x |
| Fri, 03 Nov 2023 | HK$1.6t | HK$1.4t | HK$25.0b | 12.5x | 65x | 1.2x |
| Sun, 01 Oct 2023 | HK$1.6t | HK$1.4t | HK$24.6b | 12.6x | 64.9x | 1.1x |
| Tue, 29 Aug 2023 | HK$1.6t | HK$1.4t | HK$17.6b | 12.6x | 88.7x | 1.2x |
| Thu, 27 Jul 2023 | HK$1.7t | HK$1.4t | HK$2.6b | 14.1x | 672.5x | 1.3x |
| Sat, 24 Jun 2023 | HK$1.6t | HK$1.4t | HK$3.0b | 14x | 533.3x | 1.2x |
| Mon, 22 May 2023 | HK$1.8t | HK$1.4t | HK$3.3b | 15.2x | 541x | 1.3x |
| Wed, 19 Apr 2023 | HK$2.0t | HK$1.4t | HK$3.8b | 14.3x | 523.1x | 1.4x |
| Fri, 17 Mar 2023 | HK$1.9t | HK$1.3t | HK$93.6m | 14.9x | 20215.4x | 1.4x |
| Sun, 12 Feb 2023 | HK$2.0t | HK$1.4t | HK$2.2b | 15.5x | 925.1x | 1.5x |
| Tue, 10 Jan 2023 | HK$2.0t | HK$1.4t | HK$2.2b | 15.5x | 914.6x | 1.5x |
| Thu, 08 Dec 2022 | HK$1.8t | HK$1.3t | HK$2.1b | 13.5x | 881.2x | 1.4x |
| Sat, 05 Nov 2022 | HK$1.7t | HK$1.3t | HK$1.3b | 12.5x | 1286.6x | 1.3x |
| Mon, 03 Oct 2022 | HK$1.5t | HK$1.3t | HK$3.7b | 12.9x | 396.7x | 1.1x |
| Wed, 31 Aug 2022 | HK$1.7t | HK$1.3t | HK$4.8b | 14.3x | 355.2x | 1.3x |
Price to Earnings Ratio
355.2x
Current Industry PE
- Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 71.0x which is lower than its 3-year average PE of 237x.
- The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.8x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have grown 100% per year over the last three years.
- Revenues for these companies have grown 3.8% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare sector?
| HK Market | 0.48% | |
| Healthcare | 0.90% | |
| Life Sciences | 2.82% | |
| Biotech | 1.61% | |
| Healthcare Services | 0.23% | |
| Pharma | 0.22% | |
| Healthtech | -0.46% | |
| Medical Equipment | -1.62% | |
Industry PE
- Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 3.0x.
- Analysts are expecting annual earnings growth of 66.3%, which is higher than its past year's earnings growth of 8.4% per year.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 66% over the next 5 years.
- This is better than its past earnings growth rate of 8.4% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 13% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 9926 Akeso | HK$176.90 | 6.9% +HK$10.2b | 285.4% | PS68.5x | |
| 2269 WuXi Biologics (Cayman) | HK$32.92 | 6.4% +HK$8.1b | 220.9% | PE29.3x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$466.60 | 7.5% +HK$7.5b | 184.3% | PS65.1x | |
| 1177 Sino Biopharmaceutical | HK$8.17 | 4.5% +HK$6.3b | 160.2% | PE34.4x | |
| 512 Grand Pharmaceutical Group | HK$9.70 | 15.6% +HK$4.6b | 131.0% | PE16.3x |
